SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lee Jong Seo)
 

Sökning: WFRF:(Lee Jong Seo) > (2020-2024) > Comparative safety ...

  • Kim, Min SeoKorea Univ, South Korea; Sungkyunkwan Univ, South Korea (författare)

Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2021-11-08
  • WILEY,2022
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:liu-181024
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-181024URI
  • https://doi.org/10.1002/jmv.27424DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Funding Agencies|Yonsei University College of MedicineGeneral Electric [2021-32-0049]
  • Two messenger RNA (mRNA) vaccines developed by Pfizer-BioNTech and Moderna are being rolled out. Despite the high volume of emerging evidence regarding adverse events (AEs) associated with the COVID-19 mRNA vaccines, previous studies have thus far been largely based on the comparison between vaccinated and unvaccinated control, possibly highlighting the AE risks with COVID-19 mRNA vaccination. Comparing the safety profile of mRNA vaccinated individuals with otherwise vaccinated individuals would enable a more relevant assessment for the safety of mRNA vaccination. We designed a comparative safety study between 18 755 and 27 895 individuals who reported to VigiBase for adverse events following immunization (AEFI) with mRNA COVID-19 and influenza vaccines, respectively, from January 1, 2020, to January 17, 2021. We employed disproportionality analysis to rapidly detect relevant safety signals and compared comparative risks of a diverse span of AEFIs for the vaccines. The safety profile of novel mRNA vaccines was divergent from that of influenza vaccines. The overall pattern suggested that systematic reactions like chill, myalgia, fatigue were more noticeable with the mRNA COVID-19 vaccine, while injection site reactogenicity events were more prevalent with the influenza vaccine. Compared to the influenza vaccine, mRNA COVID-19 vaccines demonstrated a significantly higher risk for a few manageable cardiovascular complications, such as hypertensive crisis (adjusted reporting odds ratio [ROR], 12.72; 95% confidence interval [CI], 2.47-65.54), and supraventricular tachycardia (adjusted ROR, 7.94; 95% CI, 2.62-24.00), but lower risk of neurological complications such as syncope, neuralgia, loss of consciousness, Guillain-Barre syndrome, gait disturbance, visual impairment, and dyskinesia. This study has not identified significant safety concerns regarding mRNA vaccination in real-world settings. The overall safety profile patterned a lower risk of serious AEFI following mRNA vaccines compared to influenza vaccines.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Jung, Se YongYonsei Univ, South Korea (författare)
  • Ahn, Jong GyunYonsei Univ, South Korea (författare)
  • Park, Se JinEulji Univ, South Korea (författare)
  • Shoenfeld, YehudaSt Petersburg State Univ, Russia; Tel Aviv Univ, Israel (författare)
  • Kronbichler, AndreasMed Univ Innsbruck, Austria (författare)
  • Koyanagi, AiUniv Barcelona, Spain; ICREA, Spain; CIBERSAM, Spain (författare)
  • Dragioti, ElenaLinköpings universitet,Avdelningen för prevention, rehabilitering och nära vård,Medicinska fakulteten,Region Östergötland, Smärt och rehabiliteringscentrum(Swepub:liu)eledr71 (författare)
  • Tizaoui, KalthoumUniv Tunis El Manar, Tunisia (författare)
  • Hong, Sung HwiYonsei Univ, South Korea (författare)
  • Jacob, LouisUniv Barcelona, Spain; Univ Versailles St Quentin Yvelines, France (författare)
  • Salem, Joe-ElieSorbonne Univ, France; Hop La Pitie Salpetriere, France (författare)
  • Yon, Dong KeonSeoul Natl Univ, South Korea (författare)
  • Lee, Seung WonSejong Univ, South Korea (författare)
  • Ogino, ShujiDana Farber Harvard Canc Ctr, MA USA; Harvard TH Chan Sch Publ Hlth, MA USA; Harvard Med Sch, MA 02115 USA; Broad Inst MIT & Harvard, MA 02142 USA (författare)
  • Kim, HannaEwha Womans Univ, South Korea (författare)
  • Kim, Jerome H.Int Vaccine Inst, South Korea (författare)
  • Excler, Jean-LouisInt Vaccine Inst, South Korea (författare)
  • Marks, FlorianInt Vaccine Inst, South Korea; Univ Cambridge, England; Univ Antananarivo, Madagascar (författare)
  • Clemens, John D.Int Vaccine Inst, South Korea; Int Ctr Diarrheal Dis Res, Bangladesh; UCLA Fielding Sch Publ Hlth, CA USA (författare)
  • Eisenhut, MichaelLuton & Dunstable Univ Hosp, England (författare)
  • Barnett, YvonneAnglia Ruskin Univ, England (författare)
  • Butler, LaurieAnglia Ruskin Univ, England (författare)
  • Ilie, Cristian PetreQueen Elizabeth Hosp Fdn Trust, England (författare)
  • Shin, Eui-CheolKorea Adv Inst Sci & Technol, South Korea; Korea Adv Inst Sci & Technol, South Korea (författare)
  • Shin, Jae IlYonsei Univ, South Korea (författare)
  • Smith, LeeAnglia Ruskin Univ, England (författare)
  • Korea Univ, South Korea; Sungkyunkwan Univ, South KoreaYonsei Univ, South Korea (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Medical Virology: WILEY94:3, s. 1085-10950146-66151096-9071

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy